Janux Therapeutics Inc
NASDAQ:JANX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.36
61.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Janux Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
923.5m USD |
-1 019%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.9B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
170.8B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
153B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.3B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.6B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
89.1B AUD |
19%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
46.3B EUR |
43%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
54.4B USD |
1%
|
Janux Therapeutics Inc
Glance View
In the realm of pioneering biotechnology companies charting new territories in cancer therapeutics, Janux Therapeutics Inc. stands out with its innovative approach to drug development. Founded with the mission to revolutionize cancer treatment, Janux focuses on creating next-generation immunotherapies designed to harness the body's immune system in a more precise and robust manner. At the heart of Janux's strategy is its proprietary Tumor Activated T Cell Engager (TRACTr) technology platform, which enables the creation of immunotherapies that activate T-cells only when they encounter tumor cells, sparing healthy tissues from off-target effects. This selectivity not only has the potential to enhance the therapeutic efficacy of their treatments but also significantly reduces adverse side effects, ultimately offering a new ray of hope for patients afflicted by hard-to-treat cancers. The financial backbone of Janux Therapeutics is rooted in its strategic partnerships and potential blockbuster drug candidates. The company capitalizes on initial funding from venture capitalists who are deeply interested in biotechnological advancements and breakthroughs. By progressing drug candidates through stages of clinical trials, Janux aims to demonstrate efficacy and safety, which could lead to lucrative licensing deals and collaborations with major pharmaceutical companies. Revenue generation is anticipated as these drugs move closer to market approval, with long-term profitability tied to successful partnerships and eventual commercialization. Through this meticulous model of development, Janux poises itself not just as an innovator in cancer treatment, but as a potentially transformative force in the biotech industry.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Janux Therapeutics Inc's most recent financial statements, the company has Net Margin of -1 019%.